Considering the superior anti-NAFLD effects of a lower dosage of PTM (10 vs. 50 mg/kg) in the murine NAFLD model, the judicious selection of dosage of FASN inhibitors may be critical to achieve certain clinical benefits. The gene discussed is FASN; the disease is metabolic dysfunction-associated steatotic liver disease.